Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy

AJ Marian, E Braunwald - Circulation research, 2017 - Am Heart Assoc
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …

Hypertrophic cardiomyopathy: the future of treatment

CV Tuohy, S Kaul, HK Song, B Nazer… - European journal of …, 2020 - Wiley Online Library
Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic disorder most often caused
by sarcomeric mutations resulting in left ventricular hypertrophy, fibrosis, hypercontractility …

Mechanisms of disease: hypertrophic cardiomyopathy

N Frey, M Luedde, HA Katus - Nature Reviews Cardiology, 2012 - nature.com
Hypertrophic cardiomyopathy (HCM) is the most-common monogenically inherited form of
heart disease, characterized by thickening of the left ventricular wall, contractile dysfunction …

Reactive oxygen species controls endometriosis progression

C Ngô, C Chéreau, C Nicco, B Weill, C Chapron… - The American Journal of …, 2009 - Elsevier
Endometriosis is associated with chronic inflammation, and reactive oxygen species (ROS)
are proinflammatory mediators that modulate cell proliferation. We have investigated …

Individualized interactomes for network-based precision medicine in hypertrophic cardiomyopathy with implications for other clinical pathophenotypes

BA Maron, RS Wang, S Shevtsov, SG Drakos… - Nature …, 2021 - nature.com
Progress in precision medicine is limited by insufficient knowledge of transcriptomic or
proteomic features in involved tissues that define pathobiological differences between …

Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence

R Spoladore, MS Maron, R D'Amato… - European heart …, 2012 - academic.oup.com
Hypertrophic cardiomyopathy (HCM) is the most common genetic heart disease, affecting
over one million individuals in Europe. Hypertrophic cardiomyopathy patients often require …

Pharmacological management of hypertrophic cardiomyopathy: from bench to bedside

C Palandri, L Santini, A Argirò, F Margara, R Doste… - Drugs, 2022 - Springer
Hypertrophic cardiomyopathy (HCM), the most common inherited heart disease, is still
orphan of a specific drug treatment. The erroneous consideration of HCM as a rare disease …

[HTML][HTML] Hypertrophic cardiomyopathy: genetics and clinical perspectives

CM Wolf - Cardiovascular diagnosis and therapy, 2019 - ncbi.nlm.nih.gov
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease and
defined by unexplained isolated progressive myocardial hypertrophy, systolic and diastolic …

Disease pathways and novel therapeutic targets in hypertrophic cardiomyopathy

H Ashrafian, WJ McKenna, H Watkins - Circulation research, 2011 - Am Heart Assoc
As described in earlier reviews in this series on the molecular basis of hypertrophic
cardiomyopathy (HCM), HCM is one of the archetypal monogenic cardiovascular disorders …

N-acetylcysteine ameliorates cisplatin-induced renal senescence and renal interstitial fibrosis through sirtuin1 activation and p53 deacetylation

C Li, N Xie, Y Li, C Liu, FF Hou, J Wang - Free Radical Biology and …, 2019 - Elsevier
The mechanism underlying the development of chronic kidney disease (CKD) after acute
kidney injury (AKI) remains unclear. Maladaptive repair has been considered an important …